Risk Stratification of Sudden Cardiac Death After Acute Myocardial Infarction
1Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Insights
Sudden death after myocardial infarction (MI) remains a significant problem. New risk stratification methods are needed to optimize implantable cardioverter-defibrillator (ICD) use beyond left ventricular ejection fraction (LVEF).
Area of Science:
- Cardiology
- Sudden Cardiac Death Research
Background:
- Mortality after myocardial infarction (MI) remains high, with sudden death accounting for 25-50% of deaths.
- Implantable cardioverter-defibrillators (ICDs) reduce arrhythmic sudden death but are costly and carry risks.
- Current risk assessment using left ventricular ejection fraction (LVEF) lacks optimal sensitivity and specificity for identifying patients who will benefit from ICDs.
Purpose of the Study:
- To review the epidemiology of sudden death post-MI.
- To discuss current sudden death risk stratification methods.
- To highlight the need for improved risk stratification beyond LVEF for optimal ICD utilization.
Main Methods:
- Review of epidemiological data on sudden death after MI.
- Discussion of existing and proposed risk stratification tools.
- Analysis of multivariable models for competing risks of death.
Main Results:
- Sudden death remains a major cause of mortality post-MI.
- LVEF is an imperfect predictor of sudden death risk and ICD benefit.
- Various novel methods are being explored for better risk stratification.
Conclusions:
- There is a critical need for validated methods to stratify sudden death risk post-MI.
- Improved risk stratification will enable more effective and appropriate use of ICDs.
- Future research should focus on developing and validating new tools beyond LVEF.
Abstract:
Despite advances in the diagnosis and treatment of acute coronary syndromes and an overall improvement in outcomes, mortality after myocardial infarction (MI) remains high. Sudden death, which is most frequently due to ventricular tachycardia or ventricular fibrillation, is the cause of death in 25% to 50% of patients with prior MI, and therefore represents an important public health problem. Use of the implantable cardioverter-defibrillator (ICD), which is the primary method of reducing the chance of arrhythmic sudden death after MI, is costly to the medical system and is associated with procedural and long-term risks. Additionally, assessment of left ventricular ejection fraction (LVEF), which is the primary method of assessing a patient's post-MI sudden death risk and appropriateness for ICD implantation, lacks both sensitivity and specificity for sudden death, and may not be the optimal way to select the subgroup of post-MI patients who are most likely to benefit from ICD implantation. To optimally utilize ICDs, it is therefore critical to develop and prospectively validate sudden death risk stratification methods beyond measuring LVEF. A variety of tests that assess left ventricular systolic function/morphology, potential triggers for ventricular arrhythmias, ventricular conduction/repolarization, and autonomic tone have been proposed as sudden death risk stratification tools. Multivariable models have also been developed to assess the competing risks of arrhythmic and non-arrhythmic death so that ICDs can be utilized more effectively. This manuscript will review the epidemiology of sudden death after MI, and will discuss the current state of sudden death risk stratification in this population.
More Related Videos
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
05:16Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
Published on: June 10, 2025
Related Concept Videos
Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome III: Diagnostic Studies
Heart Failure IV: Classification and Diagnostic Evaluation
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
